Clear Street initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $33 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with a Buy at TD Cowen
- Summit Therapeutics’ Ivonescimab: A Potential Game-Changer in NSCLC Treatment with Promising HARMONi Trial Results
- BioNTech price target lowered to $132 from $140 at Morgan Stanley
- Summit Therapeutics’ Earnings Call: Ivonescimab’s Promising Progress
- Apple reports earnings beat, China weighs trade talks with U.S.: Morning Buzz